YM BIOSCIENCES', EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREA...( MISSISSAUGA ON Aug. 21 / YM BioSc...)

MISSISSAUGA, ON, Aug. 21 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that Oncoscience AG (Wedel, Germany), its European partner for the development of the humanized EGFR-targeting monoclonal antibody, nimotuzumab, has advised that two additional late-stage trials have been cleared to commence in Europe.

- A randomized multi-centre study in which nimotuzumab and the current

standard of care (radiotherapy with concomitant and adjuvant

temozolomide) will be compared to the current standard of care in

patients with glioblastoma multiforme (GBM). This Phase III

first-line study is expected to recruit 150 patients in approximately

24 months. The primary end-point for this trial is Progression-Free

Survival with Response Rate and Symptom Control among the secondary

endpoints.

- A randomized, placebo-controlled, multi-centre Phase IIb/IIIa study

in chemotherapy-naive patients with locally advanced or metastatic

pancreatic cancer who will be treated with either gemcitabine plus

nimotuzumab or gemcitabine plus placebo. This trial is expected to

recruit 188 patients requiring approximately 24 months. The primary

end-points for this trial are Time to Tumor Progression (TTP) and

Overall Survival with Quality of Life and Response Rate among the

secondary endpoints. YM BioSciences anticipates that it will extend

the European trial in pancreatic cancer into Canada by submitting the

protocol to Canadia
'/>"/>

SOURCE YM BioSciences Inc. Copyright©2007 PR Newswire.

0 GOOD